JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

DexCom Inc

Gesloten

SectorGezondheidszorg

70.43 -0.84

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

70.41

Max

71.17

Belangrijke statistieken

By Trading Economics

Inkomsten

74M

180M

Verkoop

121M

1.2B

K/W

Sectorgemiddelde

46.87

37.461

Winstmarge

15.539

Werknemers

10,200

EBITDA

90M

309M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+38.01% upside

Dividenden

By Dow Jones

Volgende Winsten

30 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-8.3B

27B

Vorige openingsprijs

71.27

Vorige sluitingsprijs

70.43

Nieuwssentiment

By Acuity

50%

50%

147 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

DexCom Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 jul 2025, 18:41 UTC

Acquisities, Fusies, Overnames

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

Peer Vergelijking

Prijswijziging

DexCom Inc Prognose

Koersdoel

By TipRanks

38.01% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 97.06 USD  38.01%

Hoogste 106 USD

Laagste 85 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor DexCom Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

22 ratings

19

Buy

3

Hold

0

Sell

Technische score

By Trading Central

71.66 / N/ASteun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

147 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat